Superstring Capital Management LP is an SEC-registered investment adviser based in New York, NY that reports managing 1 hedge fund on Form ADV. It reports $339.5 million in regulatory assets under management. Its private funds, of all types, hold $315.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +28.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +114.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $339.5 millionForm ADV Item 5.F
- Gross assets of private funds
- $315.7 millionAll private fund types, Form ADV
- Hedge funds managed
- 12 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 305743
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +26.7% | +14.8% |
| Q1 2026 | +1.6% | -4.6% |
| Q4 2025 | +43.8% | +2.4% |
| Q3 2025 | +38.4% | +7.8% |
| Q2 2025 | +12.9% | +10.4% |
| Q1 2025 | -16.1% | -4.5% |
| Q4 2024 | -17.9% | +2.1% |
| Q3 2024 | +7.7% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Cogent Biosciences Inc$13.3 million
- Axsome Therapeutics Inc$13.2 million
- Genmab A/s$11.8 million
- Celldex Therapeutics Inc New Com New$10.7 million
- Trevi Therapeutics Inc$9.8 million
- Revolution Medicines Inc$9.6 million
- 24477v105$8.9 million
- Vir Biotechnology Inc$8.7 million
- Immunovant Inc$8.0 million
- Urogen Pharma LTD$7.0 million
As of 2026-06-30, from 13F filing by Superstring Capital Management LP.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures